NOTCH1 Mutations Are Associated with Therapy-Resistance in Patients with B-Cell Lymphoma Treated with CD20xCD3 Bispecific Antibodies
Emil Ramsø Kyvsgaard(University of Copenhagen), Simon Husby(Copenhagen University Hospital), Michael Møller(Hospital South West Jutland), Anne Ortved Gang(University of Copenhagen), Trine Grantzau(Rigshospitalet), Trine Trab(University of Copenhagen), Thomas Stauffer Larsen(Odense University Hospital), Linea Cecilie Melchior(Rigshospitalet), Lise Mette Rahbek Gjerdrum(University of Copenhagen), Carsten Utoft Niemann(Copenhagen University Hospital), Morten Grauslund(Rigshospitalet), Martin Hutchings(University of Copenhagen), Marie Fredslund Breinholt(University of Copenhagen), Lene Dissing Sjø(Rigshospitalet), Jacob Haaber Christensen(Odense University Hospital), Michael Roost Clausen(Vejle Sygehus), Anna Caroline Hasselbalch Riley(Rigshospitalet), Kirsten Grønbæk(University of Copenhagen)
Cited by 1
Related Papers
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2020|568